ANI Pharmaceuticals Inc (ANIP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ANI Pharmaceuticals Inc (ANIP) has a cash flow conversion efficiency ratio of 0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.37 Million) by net assets ($540.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ANI Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how ANI Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of ANI Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
ANI Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ANI Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hengdian Group Tospo Lighting Co Ltd
SHG:603303
|
0.100x |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
0.007x |
|
Navios Maritime Partners LP Unit
NYSE:NMM
|
0.034x |
|
Lightwave Logic Inc
NASDAQ:LWLG
|
-0.044x |
|
Inox Wind Limited
NSE:INOXWIND
|
-0.058x |
|
Streamax Technology Co Ltd
SHE:002970
|
0.051x |
|
MicroPort Scientific Corporation
F:MSK
|
-0.055x |
|
Alkami Technology Inc
NASDAQ:ALKT
|
-0.013x |
Annual Cash Flow Conversion Efficiency for ANI Pharmaceuticals Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of ANI Pharmaceuticals Inc from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of ANI Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $540.72 Million | $185.22 Million | 0.343x | +129.30% |
| 2024-12-31 | $428.53 Million | $64.02 Million | 0.149x | -42.54% |
| 2023-12-31 | $457.60 Million | $118.96 Million | 0.260x | +382.05% |
| 2022-12-31 | $338.54 Million | $-31.20 Million | -0.092x | -1095.33% |
| 2021-12-31 | $358.74 Million | $3.32 Million | 0.009x | -88.13% |
| 2020-12-31 | $195.70 Million | $15.27 Million | 0.078x | -63.62% |
| 2019-12-31 | $212.79 Million | $45.63 Million | 0.214x | -36.93% |
| 2018-12-31 | $197.26 Million | $67.07 Million | 0.340x | +50.74% |
| 2017-12-31 | $174.76 Million | $39.42 Million | 0.226x | +39.29% |
| 2016-12-31 | $169.65 Million | $27.47 Million | 0.162x | +50.16% |
| 2015-12-31 | $160.08 Million | $17.26 Million | 0.108x | -31.58% |
| 2014-12-31 | $139.78 Million | $22.03 Million | 0.158x | +217.73% |
| 2013-12-31 | $40.96 Million | $-5.48 Million | -0.134x | +85.08% |
| 2012-12-31 | $28.18 Million | $-25.28 Million | -0.897x | +29.11% |
| 2011-12-31 | $37.82 Million | $-47.87 Million | -1.266x | +39.55% |
| 2010-12-31 | $19.15 Million | $-40.10 Million | -2.094x | -79.87% |
| 2009-12-31 | $15.83 Million | $-18.43 Million | -1.164x | -3.62% |
| 2008-12-31 | $13.83 Million | $-15.54 Million | -1.124x | -4613.67% |
| 2007-12-31 | $29.73 Million | $739.99K | 0.025x | +109.00% |
| 2006-12-31 | $18.07 Million | $-5.00 Million | -0.277x | +77.28% |
| 2005-12-31 | $6.82 Million | $-8.30 Million | -1.217x | -85.52% |
| 2004-12-31 | $15.92 Million | $-10.44 Million | -0.656x | -3.15% |
| 2003-12-31 | $8.68 Million | $-5.52 Million | -0.636x | +25.81% |
| 2002-12-31 | $4.62 Million | $-3.96 Million | -0.857x | -90.38% |
| 2001-12-31 | $4.05 Million | $-1.82 Million | -0.450x | +70.17% |
| 2000-12-31 | $2.13 Million | $-3.21 Million | -1.509x | -360.05% |
| 1999-12-31 | $5.45 Million | $-1.79 Million | -0.328x | +71.62% |
| 1998-12-31 | $2.63 Million | $-3.04 Million | -1.156x | -- |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more